Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie

Amcor Plc

Air Products and Chemicals

Franklin Resources

Chevron

Essex Property Trust

Federal Realty Investment Trust

NextEra Energy

Realty Income Corp

Sysco

Target

T. Rowe Price Group

Walgreens

"Dividend Aristocrats in the S&P 500 Index have raised their annual payouts every year for at least 25 consecutive years. " - Kiplinger.com/Investing. 66 Aristocrats, screened as of August 9, 2023, represented all eleven Morningstar Sectors. Broker estimated-top-ten net gains ranged 15.54%-31.28% topped by TGT and NEE. By yield, WBA topped-all Aristocrats. Top-ten Yields from ESS, ABBV, FRT, BEN, TROW, IBM, AMCR, O, MMM, & WBA, averaged 4.78%.

3 Dividend Aristocrat Buys For August And 6 To Watch

Medtronic (MDT) is gaining from positive sales momentum with the rollout of its differentiated Hugo robotic system in many international markets.

Medtronic (MDT) Rides on Strong Global Growth, New Launches

AeroVironment

Caterpillar

Deere & Company

General Motors

Palantir Technologies

Trimble

Many attribute the recent stock surge to AI stock popularity. At the same time, it's crucial to note that numerous companies are working silently beneath the radar.

7 Companies Leading the Way in Advanced AI and Robotics

Investors are optimistic about Medtronic (MDT) on strong growth prospects within the Neurosurgery portfolio and upbeat 2024 guidance.

Here's Why You Should Invest in Medtronic (MDT) Stock Now

DUBLIN , Aug. 8, 2023 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its first quarter of fiscal year 2024 on Tuesday, August 22, 2023. A news release will be issued at approximately 5:45 a.m.

Medtronic to announce financial results for its first quarter of fiscal year 2024

Broadstone Net Lease

Bank of Nova Scotia

BRT Apartments

Cardinal Health

Chimera Investment

Canadian Imperial Bank of Commerce

Cisco Systems

Eastman Chemical

Gap Inc

GlaxoSmithKline

Iron Mountain

Illinois Tool Works

Coca-Cola

Leggett & Platt

MDU Resources Group

Medical Properties Trust

NetApp

Orion Office REIT

Oracle

Paramount Global

Philip Morris

J. M. Smucker

In July, we received a dividend income total of $1,421.13. The $200 dividend from Canada Imperial was reinvested and acquired almost 5 more shares, adding more income. July was probably one of the lowest number of stocks increasing their dividend for me.

Dividend Income Summary: Lanny's July 2023 Summary

McDonald's

PayPal

After five consecutive months of gains in the S&P 500 and Nasdaq Composite, the market might be due for a pullback. One way to protect portfolio gains is to hide in defensive stocks as we enter a seasonally weak period.

3 ‘Strong Buy' Blue-Chip Stocks You Should Be Loading Up On Now

American Tower

CVS Health

CVS Health's dividend yield is more than double the average stock in the benchmark S&P 500. American Tower is the telecommunications industry's favorite real estate investment trust.

3 Reliable Dividend Stocks With Yields Above 3% to Buy in August

Charles River Laboratories

Danaher

As a prolific cog in the economic machine, the healthcare industry has been a roller coaster ride over the past few years. With the global pandemic, economic slowdown and industry-wide disruptions in play, healthcare stocks took a major hit but are now demonstrating signs of recovery.

Buy Alert: 3 Healthcare Stocks Nearing Super Attractive Entry Points

Clorox

Ecolab

Hormel Foods

Nordson

ProShares S&P 500 Dividend Aristocrats ETF

SPDR S&P 500 ETF Trust

Stanley Black & Decker

V.F.

The ProShares S&P 500 Dividend Aristocrat ETF had a strong month in June with a gain of 8.08%, year-to-date the Fund is up 5.72%. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After nearly two full years of tracking these strategies, all 3 buy-and-hold portfolios continue to generate alpha over NOBL and SPY.

My Best Dividend Aristocrats For August 2023

Johnson & Johnson

Johnson & Johnson and Medtronic are leaders in the medical device industry and both delivered growth in the most recent quarter. One of these stocks looks like a better buy right now.

Better Medtech Buy: J&J vs. Medtronic

Apple

Amgen

Broadcom

Blackrock Inc

Bristol-Myers

Carrier Global

Chubb

Comcast

Dick's Sporting Goods

General Mills

HSBC Holdings

iShares Core S&P 500 ETF

Juniper Networks

My U.S. dividend growth portfolio, constructed in 2015, has outperformed the market by over 2% annually. The portfolio was designed to be resilient in a major stock market correction, focusing on dividend achievers with at least 10 years of dividend growth. For building a similar portfolio in 2023, I considered valuation and growth, leaning towards larger cap or mega-cap stocks, and factored in retirement income needs.

Building The Dividend Growth Portfolio In 2023

News for Medtronic Stock (MDT)